SABITALKS / Recent Advances in Hepatocellular Carcinoma Systemic Therapy
Dr. Ahmed Kaseb from University of Texas Anderson Cancer Center is going to be at SABITALKS on July 31, 2024 at 16:00.
The event will take place online.
*Zoom participation link will be active at the event time.
*Participants from outside SABITA must fill in the participation form.
Recent Advances in Hepatocellular Carcinoma Systemic Therapy / TQ Formula Therapeutic Potential in Covid-19 and Cancer
Ahmed O. Kaseb, M.D.
John E. and Dorothy J. Harris Professorship in Gastrointestinal Cancer Research Member, National Hepatobiliary Task Force, NCI, USA Tenured Professor and Director, HCC Program Clinical PI and Director, MD Anderson HCC SPORE Department of GI Medical Oncology, MD Anderson Editor-in-Chief: Journal of Hepatocellular Carcinoma
Dr. Kaseb is an endowed and tenured Professor of GI Medical Oncology at the University of Texas MD Anderson Cancer Center, in Houston, and is a member of the US National Hepatobiliary Task Force, NCI in the USA. He leads the HCC program at MD Anderson and serves as Principal Investigator and Director of MD Anderson SPORE NIH grant in HCC and PI of an RO1 grant of neoadjuvant immunotherapy in HCC.
Dr. Kaseb’s research led to initiation of multiple IND studies in all phases, first-in-humans to phase 3 trials that led to new drugs approvals and landmark publications that established new staging systems and therapeutic strategies in liver cancer, such as neoadjuvant immunotherapy in resectable HCC.
He authored and co-authored over 200 papers, abstracts, and book chapters and served on multiple national and international societies committees and study sections at NCI/NIH, and DOD, guidelines committees, and global steering committees of clinical trials that led to FDA approval of new therapies in HCC. His multidisciplinary teamwork has been awarded multi-million dollar federal, foundation and pharmaceutical grants for dozens of projects and clinical trials. He has been selected as the Editor-in-Chief of the international journal; “Journal of Hepatocellular Carcinoma” and is the founder and steering committee chair of the international HCC consortium between MD Anderson and its sister institutions.